SLC38A2

Across TCGA pan-cancer cohorts, SLC38A2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SLC38A2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where SLC38A2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SLC38A2 is over-expressed in tumor.

HNSC, LSCC, and COAD are the cancer types where SLC38A2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC38A2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	All	+1.402	<.001	12	view →
LSCC	Female	All	+1.054	<.001	8	view →
COAD	Female	All	+0.405	<.001	6	view →
LUAD	All	All	+0.226	<.001	6	view →
OV	All	All	+0.469	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

SLC38A2–HNSC

Open the HNSC breakdown →